Table 2.
Effect of IPTsc on malaria parasitaemia during the intervention period
| Study site | Study by drug regimen | No. of children | Prevalence of infection (%) | PE (95 % CI) | |
|---|---|---|---|---|---|
| Clarke [24] | Bondo | SP + AQ (four-monthly) | 2584 | 4.6 | 88 (86 to 90) |
| Placebo | 2294 | 39.7 | – | ||
| Barger [25] | Kollé | SP + AS | 91 | 6.6 | 81 (56 to 92) |
| AQ + AS | 97 | 6.2 | 81 (57 to 91) | ||
| Placebo | 96 | 34.4 | – | ||
| Nankabirwa [26] | Tororo | SP | 186 | 79.7 | 0.05 (−4 to 14) |
| SP + AQ | 200 | 43.3 | 49 (38 to 56) | ||
| DP | 198 | 11.7 | 86 (80 to 91) | ||
| Placebo | 196 | 84.6 | – | ||
| Nankabirwa [27] | Tororo | DP (monthly) | 2638a | 2 | 94 (93 to 96) |
| DP (three to five monthly) | 2644a | 18 | 54 (49 to 58) | ||
| Placebo | 2700a | 38 | – |
PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine, % percentage
aTotal tests